Oxemia^TM (Desidustat), a first-of-its-kind oral treatment in India and an alternative to injectable erythropoietin-stimulating agents (ESAs) now offers greater ease of use to patients suffering from anemia associated with Chronic Kidney Disease (CKD)

Know More

Oxemia^TM is a prescription drug and should be taken under the advice and guidance of a nephrologist or internal medicine specialist only.

Know More

Zydus' multi-pronged approach to combat the pandemic of COVID-19

Zydus' War Against
COVID-19

Explore

A legacy of 70 years in bringing innovative pharmaceutical solutions to life

About us

Driven by a passion for innovation, making a difference in the world of health and care

Innovation Excellence

Living our mission of creating healthier, happier communities globally

Zydus Srishti

Over 27000 people impacting lives across the world

Zydus group is headquartered in Ahmedabad, India, and ranks 4th in the Indian pharmaceutical industry. The group has manufacturing sites and research facilities spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim in India and in the US and Brazil.

Zydus’ global business has a strong presence in the regulated markets of the US, Europe (France and Spain) and in the high profile markets of Latin America and South Africa. It is also present in a big way in 25 other emerging markets worldwide.

Where Innovation Shapes Healthcare Solutions

Zydus’ Innovation programme is spearheaded by 1400 researchers across 19 sites, working on differentiated medicines for the future.
From NCEs to vaccines, biosimilars and niche technologies, the group is exploring
different ideas and concepts, innovating constantly.

Major Areas of Research

NCE Research

Cardio-Metabolic diseases
Inflammation & pain
Oncology

Biologics

Biosimilar Therapeutic proteins
Biosimilar Monoclonal antibodies
Biobetters and Novel biologics

Vaccines

Infectious diseases

Innovation that bridges unmet healthcare needs.

Twinrab^TM : A Breakthrough innovation in rabies PEP

World’s First Novel Rabies Monoclonal Antibodies (mAbs) cocktail containing Docaravimab and Miromavimab, providing dual protection against rabies.

Lipaglyn - Novel drug to treat diabetic dyslipidemia, a global, unmet healthcare need.

The first NCE from an Indian research pipeline to move from the lab to the market.

Exemptia - The world’s first biosimilar of Adalimumab, the largest selling therapy globally for treating auto immune disorders.

Provides a new lease of life to Indian patients of inflammatory arthritis, who did not have access to this revolutionary therapy, so far.

Vaxiflu-4 - India’s 1st Tetravalent Inactivated Influenza vaccine.

The vaccine provides protection from the four influenza viruses- H1N1, H3N2, Type B (Brisbane) and Type B (Phuket).

State-of-the-art manufacturing capabilities.

Manufacturing

As one of the key players amongst the pharmaceutical manufacturing companies, the group has manufacturing capabilities across the entire pharmaceutical value chain: including formulations, APIs, vaccines, biosimilars, complex products (transdermals, topical etc.), animal health products and wellness products. It has more than 30 manufacturing plants worldwide including India, Brazil and USA.